Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics PLC, a Main Market-listed biotech firm specializing in groundbreaking immuno-oncology medicines, has announced SP Angel Corporate Finance LLP as its new broker. The company is currently developing a portfolio of five novel anti-cancer treatments, each demonstrating significant pre-clinical success and protected by patents. These developments signify Roquefort Therapeutics’ strategic advancement in the biotechnology sector and its commitment to combating cancer through innovative therapies.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
